扩大EUS的范围:EUS引导下的肾上腺少转移疾病的基准定位和细针活检

iGIE Pub Date : 2024-12-01 DOI:10.1016/j.igie.2024.08.002
Ricardo Marrero Torres MD , Hari Gopakumar MD , Dushyant Singh Dahiya MD , Aqsa Khan MD , Uday Patel DO , Sahib Singh MD , Talia Malik MD , Marzena Muller MD , Mariajose Rojas de Leon MD , Neil R. Sharma MD
{"title":"扩大EUS的范围:EUS引导下的肾上腺少转移疾病的基准定位和细针活检","authors":"Ricardo Marrero Torres MD ,&nbsp;Hari Gopakumar MD ,&nbsp;Dushyant Singh Dahiya MD ,&nbsp;Aqsa Khan MD ,&nbsp;Uday Patel DO ,&nbsp;Sahib Singh MD ,&nbsp;Talia Malik MD ,&nbsp;Marzena Muller MD ,&nbsp;Mariajose Rojas de Leon MD ,&nbsp;Neil R. Sharma MD","doi":"10.1016/j.igie.2024.08.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Radiation therapy, including Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT), is a crucial treatment for various malignancies, though side effects often arise from radiation exposure to healthy tissues. Fiducial markers are used in SBRT to optimize tumor targeting and minimize damage to surrounding tissues. Traditionally, fiducials are placed surgically or percutaneously, but EUS offers a safer, less invasive, and potentially cost-effective alternative. While fiducial placement within the pancreas has been well-studied, there are limited data on EUS-guided fiducial marker placement in non-GI organs, particularly the adrenal glands.</div></div><div><h3>Methods</h3><div>This retrospective case series evaluated EUS-guided fiducial marker placement in the left adrenal gland in 6 patients from 2020 to 2023. Patients were selected following multidisciplinary tumor board discussions, and all procedures were performed using a 22-gauge Menghini-tip needle under EUS guidance. Data were collected on patient demographics, tumor characteristics, technical success, and clinical outcomes following fiducial placement.</div></div><div><h3>Results</h3><div>The procedure was technically successful in all patients, with no reported adverse events. Four fiducials were placed in each patient, aiding SBRT planning. Five patients proceeded with SBRT, and 80% achieved a complete local response on radiological follow-up. No significant fiducial migration was noted. The findings suggest that EUS-guided fiducial placement for adrenal tumors is safe and effective.</div></div><div><h3>Conclusion</h3><div>This is the first case series demonstrating the safety and technical success of EUS-guided fiducial placement in the adrenal gland. This technique offers an alternative to more invasive approaches, facilitating precision radiotherapy for adrenal metastases, and highlights the expanding role of interventional endoscopists in oncology care. Further prospective studies are needed to validate these findings and expand their clinical application.</div></div>","PeriodicalId":100652,"journal":{"name":"iGIE","volume":"3 4","pages":"Pages 521-526"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expanding the boundaries of EUS: EUS-guided fiducial placement and fine-needle biopsy in oligometastatic disease of the adrenal gland\",\"authors\":\"Ricardo Marrero Torres MD ,&nbsp;Hari Gopakumar MD ,&nbsp;Dushyant Singh Dahiya MD ,&nbsp;Aqsa Khan MD ,&nbsp;Uday Patel DO ,&nbsp;Sahib Singh MD ,&nbsp;Talia Malik MD ,&nbsp;Marzena Muller MD ,&nbsp;Mariajose Rojas de Leon MD ,&nbsp;Neil R. Sharma MD\",\"doi\":\"10.1016/j.igie.2024.08.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Radiation therapy, including Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT), is a crucial treatment for various malignancies, though side effects often arise from radiation exposure to healthy tissues. Fiducial markers are used in SBRT to optimize tumor targeting and minimize damage to surrounding tissues. Traditionally, fiducials are placed surgically or percutaneously, but EUS offers a safer, less invasive, and potentially cost-effective alternative. While fiducial placement within the pancreas has been well-studied, there are limited data on EUS-guided fiducial marker placement in non-GI organs, particularly the adrenal glands.</div></div><div><h3>Methods</h3><div>This retrospective case series evaluated EUS-guided fiducial marker placement in the left adrenal gland in 6 patients from 2020 to 2023. Patients were selected following multidisciplinary tumor board discussions, and all procedures were performed using a 22-gauge Menghini-tip needle under EUS guidance. Data were collected on patient demographics, tumor characteristics, technical success, and clinical outcomes following fiducial placement.</div></div><div><h3>Results</h3><div>The procedure was technically successful in all patients, with no reported adverse events. Four fiducials were placed in each patient, aiding SBRT planning. Five patients proceeded with SBRT, and 80% achieved a complete local response on radiological follow-up. No significant fiducial migration was noted. The findings suggest that EUS-guided fiducial placement for adrenal tumors is safe and effective.</div></div><div><h3>Conclusion</h3><div>This is the first case series demonstrating the safety and technical success of EUS-guided fiducial placement in the adrenal gland. This technique offers an alternative to more invasive approaches, facilitating precision radiotherapy for adrenal metastases, and highlights the expanding role of interventional endoscopists in oncology care. Further prospective studies are needed to validate these findings and expand their clinical application.</div></div>\",\"PeriodicalId\":100652,\"journal\":{\"name\":\"iGIE\",\"volume\":\"3 4\",\"pages\":\"Pages 521-526\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iGIE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949708624001079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iGIE","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949708624001079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

放射治疗,包括强度调制放射治疗(IMRT)和立体定向体放射治疗(SBRT),是各种恶性肿瘤的重要治疗方法,尽管辐射暴露于健康组织通常会产生副作用。在SBRT中使用基准标记物来优化肿瘤靶向并最大限度地减少对周围组织的损伤。传统上,基准是通过手术或经皮放置的,但EUS提供了一种更安全、侵入性更小、潜在成本效益更高的替代方法。虽然在胰腺内的基准放置已经得到了很好的研究,但在非胃肠道器官,特别是肾上腺中,eus引导的基准标记物放置的数据有限。方法回顾性分析2020年至2023年6例eus引导下左肾上腺基准标志物放置的病例。在多学科肿瘤委员会讨论后选择患者,所有手术均在EUS指导下使用22号menghini针尖进行。数据收集了患者人口统计学、肿瘤特征、技术成功和基准放置后的临床结果。结果手术在技术上是成功的,没有不良事件的报道。每位患者放置4个基准,以辅助SBRT计划。5例患者接受了SBRT治疗,80%的患者在放射学随访中获得了完全的局部缓解。没有注意到明显的基准迁移。研究结果提示eus引导下肾上腺肿瘤基准点置入术是安全有效的。结论:这是第一个证明eus引导下肾上腺基底置入术安全性和技术成功的系列病例。这项技术提供了一种替代侵入性方法的方法,促进了肾上腺转移瘤的精确放疗,并突出了介入内窥镜医师在肿瘤治疗中的作用。需要进一步的前瞻性研究来验证这些发现并扩大其临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Expanding the boundaries of EUS: EUS-guided fiducial placement and fine-needle biopsy in oligometastatic disease of the adrenal gland

Background

Radiation therapy, including Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT), is a crucial treatment for various malignancies, though side effects often arise from radiation exposure to healthy tissues. Fiducial markers are used in SBRT to optimize tumor targeting and minimize damage to surrounding tissues. Traditionally, fiducials are placed surgically or percutaneously, but EUS offers a safer, less invasive, and potentially cost-effective alternative. While fiducial placement within the pancreas has been well-studied, there are limited data on EUS-guided fiducial marker placement in non-GI organs, particularly the adrenal glands.

Methods

This retrospective case series evaluated EUS-guided fiducial marker placement in the left adrenal gland in 6 patients from 2020 to 2023. Patients were selected following multidisciplinary tumor board discussions, and all procedures were performed using a 22-gauge Menghini-tip needle under EUS guidance. Data were collected on patient demographics, tumor characteristics, technical success, and clinical outcomes following fiducial placement.

Results

The procedure was technically successful in all patients, with no reported adverse events. Four fiducials were placed in each patient, aiding SBRT planning. Five patients proceeded with SBRT, and 80% achieved a complete local response on radiological follow-up. No significant fiducial migration was noted. The findings suggest that EUS-guided fiducial placement for adrenal tumors is safe and effective.

Conclusion

This is the first case series demonstrating the safety and technical success of EUS-guided fiducial placement in the adrenal gland. This technique offers an alternative to more invasive approaches, facilitating precision radiotherapy for adrenal metastases, and highlights the expanding role of interventional endoscopists in oncology care. Further prospective studies are needed to validate these findings and expand their clinical application.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信